Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
|Articles|December 7, 2021
Daily OTC Pearl: Zarbee’s for Children's Cough
Author(s)Saro Arakelians, PharmD
Advertisement
OTC/Lifestyle Pearl of the Day: Zarbee’s
Indication: Zarbee’s is indicated for children’s cough.
Insight:
- Zarbee’s contains vitamin C, vitamin D, and zinc.
- Dosing is suggested 3 ml for children 2 to 12 months of age and 4 ml for children 1 to 3 years of age.
- Zarbee’s is safe and effective for infants 2 months of age and older.
- Zarbee’s comes in different flavors, such as berry and grape.
- Directions: Shake well before using with a suggested 2 servings in 24 hours.
Sources:
Advertisement
Related to this article
Insulin efsitora alfa-gobe (Onswik; Eli Lilly) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, whereas sulfonylureas signaled faster decline without it.
Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.
A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
Severe Asthma's Effects May Extend Beyond the Lungs, Brain Imaging Study Suggests
3
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
4
Alcohol and GLP-1 Therapy: Key Counseling Points for Pharmacists
5